Glasgow L A, Crane J L, Kern E R, Youngner J S
Cancer Treat Rep. 1978 Nov;62(11):1881-8.
Murine interferon inhibited the growth of a continuous line of osteogenic sarcoma cells in tissue culture. Inhibition of tumor cell growth was documented by decreased clone formation in liquid medium, decreased tumor cell counts in monolayer cultures, suppression of colony formation in semi-solid agar, and decreased uptake of 3H-thymidine by the osteogenic sarcoma cells in culture. The capacity of anti-interferon antibody to block the tumor cell growth inhibitory activity of the interferon preparation suggested that interferon itself is the biologically active component of the interferon preparations. In vivo, a 7-day course of 30,000-60,000 units/day of type I interferon prepared in cell cultures either completely inhibited or delayed the appearance of tumors in experimental animals inoculated with osteogenic sarcoma cells by the sc route. The therapeutic efficacy of a preparation of murine sera containing type II interferon as well as other lymphokine activity was compared with the type I interferon preparation. Animals treated with 600 units of type II interferon were protected against tumor development as effectively as with 60,000 units/day of type I.
小鼠干扰素在组织培养中抑制了骨肉瘤细胞连续系的生长。通过液体培养基中克隆形成减少、单层培养中肿瘤细胞计数减少、半固体琼脂中集落形成受抑制以及培养的骨肉瘤细胞对³H-胸腺嘧啶核苷摄取减少来证明肿瘤细胞生长受到抑制。抗干扰素抗体阻断干扰素制剂的肿瘤细胞生长抑制活性的能力表明，干扰素本身是干扰素制剂的生物活性成分。在体内，每天30000 - 60000单位、为期7天的细胞培养制备的I型干扰素疗程，完全抑制或延迟了通过皮下途径接种骨肉瘤细胞的实验动物中肿瘤的出现。将含有II型干扰素以及其他淋巴因子活性的小鼠血清制剂的治疗效果与I型干扰素制剂进行了比较。用600单位II型干扰素治疗的动物对肿瘤发展的保护效果与每天60000单位I型干扰素的效果一样有效。
